Table 1.
Baseline characteristics of patients enrolled in BRUISE CONTROL-1 and -2 trials
| Characteristics | All patients in Bruise CONTROL-1 and -2 trials that underwent CIED implantation (N = 1308, 661, and 647, respectively) |
|---|---|
| Age (years ± SD) | 72.7 ± 9.7 |
| Male sex | 950 (72.6%) |
| Body mass indexa | 28.5 ± 5.6 |
| Stroke | 186 (14.2%) |
| Transient ischaemic attack | 172 (13.2%) |
| Peripheral embolus | 36 (2.8%) |
| Systemic hypertension | 951 (72.7%) |
| Diabetes mellitus | 474 (36.2%) |
| Cardiomyopathy | 744 (56.9%) |
| Warfarina | 661 (50.5%) |
| Bridging heparin | 326 (24.9%) |
| Continued coumadin | 335 (25.6%) |
| Interrupted DOAC | 328 (25.1%) |
| Continued DOAC | 319 (24.4%) |
| Aspirin | 371 (28.4%) |
| New implant of a pacemaker | N = 341 |
| Single | 156 (45.8%) |
| Dual | 163 (47.8%) |
| Cardiac resynchronization | 22 (6.5%) |
| New implant of an implantable cardioverter-defibrillator | N = 315 |
| Single | 142 (45.1%) |
| Dual | 61 (19.4%) |
| Cardiac resynchronization | 112 (35.6%) |
| Device replacement or revision | N = 652 |
| Pulse generator change only | 229 (35.1%) |
| Pulse generator change with additional interventionsa | 177 (27.2%) |
| Other | 9 (1.4%) |
| Duration of procedure (min), median (IQR) | 45 (28–70) |
Data are expressed as N (%), median (IQR), mean ± standard deviation (SD), or n/N (%).
CIED, cardiac implantable electronic device; DOAC, direct oral anticoagulant.
a
Only patients enrolled in Bruise CONTROL-1 trial were on Warfarin. These variables were available only for patients enrolled in the BRUISE CONTROL-2 trial.